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Genome-wide association studies that scan the genome for common genetic variants associated with phenotype
have greatly advanced medical knowledge. Hyperuricemia is no exception, with 28 loci identified. However, genetic
control of pathways determining gout in the presence of hyperuricemia is still poorly understood. Two important
pathways determining hyperuricemia have been confirmed (renal and gut excretion of uric acid with glycolysis
now firmly implicated). Major urate loci are SLC2A9 and ABCG2. Recent studies show that SLC2A9 is involved in
renal and gut excretion of uric acid and is implicated in antioxidant defense. Although etiological variants at SLC2A9
are yet to be identified, it is clear that considerable genetic complexity exists at the SLC2A9 locus, with multiple
statistically independent genetic variants and local epistatic interactions. The positions of implicated genetic variants
within or near chromatin regions involved in transcriptional control suggest that this mechanism (rather than
structural changes in SLC2A9) is important in regulating the activity of SLC2A9. ABCG2 is involved primarily in
extra-renal uric acid under-excretion with the etiological variant influencing expression. At the other 26 loci,
probable causal genes can be identified at three (PDZK1, SLC22A11, and INHBB) with strong candidates at a further
10 loci. Confirmation of the causal gene will require a combination of re-sequencing, trans-ancestral mapping,
and correlation of genetic association data with expression data. As expected, the urate loci associate with gout,
although inconsistent effect sizes for gout require investigation. Finally, there has been no genome-wide association
study using clinically ascertained cases to investigate the causes of gout in the presence of hyperuricemia. In such
a study, use of asymptomatic hyperurcemic controls would be expected to increase the ability to detect genetic
associations with gout.Introduction
Hyperuricemia is necessary but not sufficient for gout.
Gout is typically characterized by recurrent self-resolving
attacks of acute inflammatory arthritis and occurs in about
a quarter of people with elevated serum urate levels (hy-
peruricemia) [1]. The metatarsal-phalangeal joint of the
big toe is most often affected, but gout commonly affects
other joints. Two important physiological mechanisms
determine hyperuricemia: (a) increased production of the
urate in the liver from dietary and endogenous substrates
that raise purine levels and (b) reduced renal and gut
excretion of uric acid (Figure 1). In the presence of hy-
peruricemia, factors controlling the formation of mono-
sodium urate (MSU) crystals in synovial fluid and the
subsequent innate immune inflammatory response areCorrespondence: tony.merriman@otago.ac.nz
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unless otherwise stated.relatively poorly understood. However, activation of
Toll-like receptors and inflammasome-mediated release
of the pro-inflammatory cytokine interleukin-1β is known
to be a central pathway [2]. Like any other complex pheno-
type, hyperuricemia and gout result from the interplay be-
tween inherited genetic risk variants and environmental
exposures [3]. The genetic component will be discussed in
this review, and environmental exposures that interact with
genetic risk variants will also be considered.
A genome-wide association study (GWAS) scans the
genome, in an unbiased fashion using common genetic
variants (typically single-nucleotide polymorphisms), for
loci causally associated with a particular phenotype. Genes
contained within the associated loci are candidates for in-
volvement in causal pathogenic pathways. Köttgen and
colleagues [4] reported, in a GWAS of more than 140,000
European individuals, statistically significant associations
of 28 separate genetic loci with serum urate levels. This
study confirmed the association with urate levels of 10 lociis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 The uric acid transportasome. The current understanding of uric acid transport in the proximal renal tubule is presented.
Carboxylates accumulate in the tubular cell through sodium-dependent monocarboxylate transporters SLC5A8 and SLC5A12 and through
SLC13A3. Uric acid enters the cell in exchange for carboxylate via apical URAT1 and apical OAT4. Apical SLC2A9v2 plays a significant role in uric
acid reabsorption within the collecting duct, the reabsorbed uric acid exiting the cell through basolateral SLC2A9v1 in the proximal tubule. For
efflux of uric acid into the lumen, MRP4, a voltage-driven organic anion transporter (vOAT1/NPT1), and NPT4 are candidates. OAT1 and OAT3 are
known to transport uric acid, although the direction of transport is not clear. PDZK1 is a scaffolding protein involved in assembly of a transporter
complex in the apical membrane. Genetic variation in SLC2A9, ABCG2, URAT1, NPT1, OAT4, and PDZK1 is associated with serum urate levels
and gout.
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elsewhere [8-11], the 10 are dominated by loci contain-
ing genes that were either known (SLC22A11/OAT4,
SLC22A12/URAT1, SLC17A1/NPT, and PDKZ1) or novel
(SLC2A9/GLUT9 and ABCG2) renal and gut transporters
of uric acid. The GCKR (glucokinase regulatory protein)
locus implicates production of urate by glycolysis, but the
functional relevance of the remaining loci (SLC16A9/MCT9, INHBC, and RREB1) is unclear, although MCT9
may be a renal sodium transporter and has been linked to
urate via carnitine metabolism [6]. Predictably most, but
not all, of these 10 loci consistently associate with gout in
multiple ancestral groups [4,12,13].
The lead associated genetic variants at SLC2A9 and
ABCG2 collectively explain, depending on sex, 3% to
4% of the variance in urate levels. On average, the
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0.373 mg/dL (0.022 mmol/L) and the urate-raising al-
lele at ABCG2 by 0.217 mg/dL (0.013 mmol/L), both of
which are clinically significant amounts [4]. SLC2A9
and ABCG2 have equivalent effects in men; SLC2A9
has a stronger effect in women than men and vice versa
for ABCG2 [4]. Sex-specific effects aside, both loci (in par-
ticular, SLC2A9) exert very strong control on urate levels,
when compared with the effect of the other 26 confirmed
urate loci that collectively explain a similar proportion of
variance. Thus, there is considerable research interest in
understanding the molecular basis of urate control by
SLC2A9 and ABCG2 and their clinical significance.
Review
The emerging role of SLC2A9 in metabolism and cancer
A major site of expression of SLC2A9 is the kidney,
where it is a voltage-dependent uric acid transporter
[14,15]. Genotype-specific expression data are consistent
with the possibility that the major causal serum urate-
raising variant (that has not yet been genetically pin-
pointed) increases the expression levels of an SLC2A9
isoform (SLC2A9-S) that has a 28-residue portion missing
from the N-terminus [16,17]. This isoform is expressed on
the apical (urine) side of the collecting duct, where it pre-
sumably increases reuptake of secreted uric acid, whereas
the full-length version (SLC2A9-L) is expressed on the
basolateral side [14]. Combined with its expression on the
basolateral membrane of hepatocytes [18], where urate is
generated, the membrane potential would ensure that the
SLC2A9-L isoform is responsible for transport of uric acid
into the bloodstream [19]. With the caveat that results
from SLC2A9-inactivation studies in the mouse can only
be extrapolated to humans with much caution (given the
presence of active urate oxidase (uricase) in mice but
not humans), a recent study demonstrates that SLC2A9
is also an important basolateral uric acid efflux trans-
porter into the gut enterocyte [20]. Interestingly, mice
with a gut-specific SLC2A9 knockout developed a meta-
bolic syndrome-like condition in addition to hyperurice-
mia [20]. In mice a hepatocyte-specific SLC2A9 knockout
develops severe hyperuricemia, consistent with a role for
SLC2A9 in hepatic uptake of uric acid [18]. Because of the
presence of uricase, the urate chemical gradient over-
comes the membrane potential so that SLC2A9 can
transport urate into liver cells. This contrasts with
humans, in whom SLC2A9 transports urate out of the
hepatocyte [21].
One reason that humans and higher apes have higher
urate levels is the postulated function of urate as an anti-
oxidant [22], replacing ascorbic acid as a major endogen-
ous antioxidant in human evolution [23]. Consistent with
this hypothesis, intracellular reactive oxygen species (ROS)
in cell culture are reduced by physiological levels of urate[24]. Interestingly, oxidative stress induces SLC2A9
transcription and expression in a manner dependent on
transcriptional control by the p53 tumor suppressor
[24]. Inhibition of SLC2A9 activity by use of small inter-
fering RNAs or the urate-lowering drugs probenecid
and benzbromarone increases ROS levels in a urate-
dependent manner and increases susceptibility of cancer
cells to apoptotic cell death induced by the chemothera-
peutic agent cisplatin [24]. Notably, samples from four
tumor types (prostate, renal, testis, and andrenal) showed
reduced SLC2A9 expression, and survival is better in gas-
tric cancers with higher SLC2A9 expression. Collectively,
these data implicate a role for SLC2A9 in countering
intracellular ROS by transport of urate (which reduces
ROS) and provide support for the controversial hypothesis
(based on observational data) linking uric acid to protec-
tion from cancer [22,25]. There could be therapeutic po-
tential in inhibiting SLC2A9 in order to chemosensitize
cancer cells by increasing ROS levels [24].
The hepatic metabolism of fructose generates urate
through generation of ADP and catabolism through the
purine degradation pathway and is one biochemical ex-
planation for the association of sugar-sweetened bever-
age (SSB) consumption with urate levels and the risk of
gout [26,27]. Given that SLC2A9 also transports fructose
and glucose [19], it is reasonable to hypothesize that
fructose could also directly interfere with renal uric acid
transport. Therefore, a recent clinical study examined
the SLC2A9 genotype-dependent acute hyperuricemic
response to a fructose load [28]. When a genetic variant
(rs11942223) largely equivalent to the most strongly as-
sociated SLC2A9 variant in the GWAS by Köttgen and
colleagues [4] (Table 1) was used, the urate-lowering al-
lele was associated with an attenuated hyperuricemic re-
sponse and increased fractional excretion of uric acid
(FEUA) in people of European ancestry (Figure 2) [28].
However, despite an appreciable prevalence in participants
of New Zealand Polynesian (Maori and Pacific) ancestry
(18% versus 32% in Europeans), there was no relationship
between positivity for the urate-raising allele and the
hyperuricemic and FEUA response to the fructose load,
despite prior evidence for association of rs11942223 with
gout in Polynesians [29]. It is possible that there is a
Polynesian-specific genetic variant in SLC2A9 that encodes
a functional effect that overrides the genotype-specific
FEUA effect seen in European Caucasians.
An epidemiological observational study also investi-
gated the hypothesis that simple sugar (in the form of
SSBs) interacts with the SLC2A9 genotype in influen-
cing serum urate levels and the risk of gout [26]. Upon
exposure to SSB, the normally urate-lowering allele at
the rs11942223 variant has a transmutation of effect
and raises urate in response to SSB, an effect not seen
with artificially sweetened beverages (Figure 2). A similar
Table 1 Summary of the 28 genome-wide significant urate loci detected by Köttgen and colleagues [4]
GRAIL gene Effect size (male/femalea),
mg/dL





Rs1471633 PDZK1 0.059 No Within PDZK1 PDZK1 -
Rs1260326 GCKR 0.074 (0.091/0.063) Yes Spans >20 genes - GCKR
Rs12498742 SLC2A9 0.373 (0.269/0.460) Yes Spans 4 genes SLC2A9 -
Rs2231142 ABCG2 0.217 (0.280/0.181) Yes Spans 4 genes ABCG2 -
Rs675209 RREB1 0.061 Yes Upstream and
within RREB1
- RREB1
Rs1165151 SLC17A3 0.091 No Spans 20 genes - SLC17A1-A4
Rs1171614 SLC16A9 0.079 No Spans 2 genes - -
Rs2078267 SLC22A11 0.073 Yes Within SLC22A11 SLC22A11 -
Rs478607 SLC22A12 0.047 Yes Spans 6 genes - SLC22A12
Rs3741414 INHBC 0.072 (0.091/0.057) No Spans 7 genes - -
New loci
Rs11264341 PKLR 0.050 No Spans 2 genes - -
Rs17050272 INHBB 0.035 No Intergenic INHBB -
Rs2307384 ACVR2A 0.029 No Spans 3 genes - -
Rs6770152 MUSTN1 0.044 No Spans 3 genes - -
Rs17632159 TMEM171 0.039 No Intergenic - -
Rs729761 VEGFA 0.047 No Intergenic - -
Rs1178977 MLXIPL 0.047 No Spans 5 genes - MLXIPL
Rs10480300 PRKAG2 0.035 No Within PRKAG2 - PRKAG2
Rs17786744 STC1 0.029 No Intergenic - -
Rs2941484 HNF4G 0.044 No Within HNF4G HNF4G
Rs10821905 ASAH2 0.057 No Within A1CF A1CF
Rs642803 LTBP3 0.036 No Spans 6 genes - -
Rs653178 PTPN11f 0.035 No Spans 3 genes - -
Rs1394125 NRG4 0.043 (0.061/0.032) Yes Spans 4 genes - -
Rs6598541 IGF1R 0.043 Yes Within IGFR1 - IGFR1
Rs7193778 NFAT5 0.046 Yes Intergenic - -
Rs7188445 MAF 0.032 No Intergenic - -
Rs7224610 HLF 0.042 Yes Within HLF - HLF
Rs2079742 C17ORF82 0.043 No Downstream and
within BCAS3
- -
Rs164009 PRPSAP1 0.028 No Within QRICH2 - -
aMale and female effect sizes are given for loci where there was a significant sex-specific difference. bFractional excretion of uric acid (FEUA) was tested by Köttgen
and colleagues [4] on a considerably smaller subset (n = 6,799), meaning that inadequate power may contribute to lack of association seen at loci of weaker
effect. cA probable causal gene either has very strong functional evidence (SLC2A9 and ABCG2) or has strong functional evidence combined with association signal
restricted to the gene (PDZK1 and SLC22A11) or has very strong expression single-nucleotide polymorphism (eSNP) evidence (INHBB). dA ‘strongest candidate’ is
listed when the locus contains a candidate with strong functional evidence (GCKR, SLC17A1-A4, and SLC22A12) or has the association signal tightly restricted to
the named gene or has strong eSNP evidence (MLXIPL). eRREB1, ras responsive element (zinc-finger) binding protein, has been genetically implicated in type 2
diabetes associated end-stage kidney disease [60]. PRKAG2, protein kinase, AMP-activated, gamma 2 non-catalytic subunit, has been genetically implicated in
blood pressure control [61]. HNF4G, hepatocyte nuclear factor 4G, has been genetically implicated in obesity [62]. MLXIPL, carbohydrate element-responsive
binding protein, has been identified as a pleiotropic gene for metabolic syndrome and inflammation [63]. fPTPN11 is approximately 1 Mb downstream of the
association signal and does not harbor any association signal. A1CF, APOBEC1 (APOB mRNA editing enzyme) complementation factor; GRAIL, Gene Relationships
Across Implicated Loci; HLF, hepatic leukemia factor; IGFR1, insulin-like growth factor 1 receptor.
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state of knowledge and given the complexity of urate
transport in the renal tubule, it is difficult to propose aplausible mechanism to explain this non-additive inter-
action. The epidemiological observations also are incon-
sistent with the increased FEUA in response to an acute
AB
Figure 2 Interaction between SLC2A9 genotype and sugar exposure. In both panels, the genetic marker used was rs11942223 for which
the C-positive genotype associates with reduced serum urate. (A) Effect of SLC2A9 genotype on acute response to a fructose load. Change in
serum urate is shown on the left, fractional excretion of uric acid (FEUA) on the right. The genotype differences were statistically significant for
Europeans (top graphs) but not for Polynesians (bottom graphs). Figure taken from Dalbeth and colleagues [28]. (B) The non-additive interaction
of sugar-sweetened beverage (SSB) consumption with SLC2A9 genotype in influence of urate levels in Europeans in the Atherosclerosis Risk in
Communities data set [26]. Exposure to artificially (diet) sweetened beverages does not influence the urate-lowering effect of the C-positive
genotypes. However, exposure to SSB reverses the urate-lowering effect of the C-positive genotype. The y-axis corresponds to change in urate
per consumption category as defined by Batt and colleagues [26]. Data taken from Table 4 of Batt and colleagues [26].
Merriman Arthritis Research & Therapy  (2015) 17:98 Page 5 of 13fructose load associated with the urate-lowering allele,
suggesting that distinct biological mechanisms underlie
the observation by Dalbeth and colleagues [28] and the
interaction data reported by Batt and colleagues [26].
The effects of chronic exposure to fructose-containing
SSB would more likely involve other mechanisms (forexample, epigenetic) that influence the expression and
activity of SLC2A9.
Genetic complexity at SLC2A9
The urate association signal at the SLC2A9 locus is
extensive with hundreds of genetic variants extremely
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passing a very large region (500 kb) and two genes
(SLC2A9 andWDR1) (Figure 3) [4].WDR1 encodes a pro-
tein involved in disassembly of actin fibers that has been
implicated in carditis - not an obvious urate-influencing
gene. It is thus difficult to determine whether the genetic
effect at SLC2A9 is caused by a single genetic variant with
very strong effect that drives the widespread association
owing to extensive intermarker ‘linkage disequilibrium’.
This can be studied by ‘conditional analysis’, whereby the
association with phenotype of other variants at a locus is
tested conditionally on the effect of the strongest associ-
ated variant at the locus. Köttgen and colleagues [4]
attempted to address this important question and con-
cluded that there was no evidence for multiple independ-
ent effects. However, their approach was dictated by a
limitation inherent in meta-analyses from many separate
studies (n = 48 in their case) in that summary level statis-
tics from each of the studies are combined and it is not
possible (for ethical and practical reasons) to combine
data from individual participants.
In contrast to the findings of Köttgen and colleagues [4],
the possibility of independent effects at SLC2A9 is sup-
ported by two studies. The first is a GWAS of serum urate
levels in East Asians [30]. As in Europeans, the strongest
genome-wide association with urate was at SLC2A9, but
with a different single-nucleotide polymorphism (SNP)
variant (rs3775948). The most strongly associated variant
in the study by Köttgen and colleagues [4] (rs12498742)
was not associated in the East Asian GWAS and this wasFigure 3 Genetic complexity of association with urate at SLC2A9. The
SNP-SNP interactions that are present at the SLC2A9 locus and that concen
Köttgen and colleagues [4], demonstrates the extent of extremely strong a
urate-associated copy number variants identified by Scharpf and colleague
study because Wei and colleagues [34] used Human Genome Project NCBI
National Center for Biotechnology Information; SNP, single-nucleotide polyprobably because of the rarity of the minor allele (preva-
lence of approximately 1%). This suggests that there are at
least two causal variants controlling urate levels at
SLC2A9. The second study was a GWAS testing for asso-
ciation of common copy number variation with serum
urate in Europeans [31]. This type of variation occurs
when chromosomal segments over 1 kb in length deviate
from the diploid state, and is a genetic and evolutionary
mechanism that can generate significant changes in gene
expression from a single mutation event. Examples are the
immune CCL3L1 and FCGR3B genes that vary from zero
to copy number of greater than four in the human gen-
ome. Copy number of these genes is a risk factor for auto-
immune disease [32,33]. The only copy number variations
associated with urate in the GWAS at a genome-wide
level of significance were two separate segments at the
SLC2A9 locus [31]. These variants are 200 kb and 350 kb
upstream of SLC2A9 (Figure 3) and deletion of 12-kb and
7.5-kb segments, respectively, at each copy number vari-
ant associates with, respectively, decreased and increased
urate levels of approximately 5% in women and approxi-
mately 1% in men [31]. Importantly, by conditional ana-
lysis, the association of these copy number variants was
genetically independent of the previously reported effect
at SLC2A9 [4]. Thus, there is evidence for three inde-
pendent variants in SLC2A9 that influence urate levels
in Europeans and for a separate variant in East Asians.
Although it is not known whether either of the copy
number variants is causal or in strong linkage disequi-
librium with an unidentified causal variant, at least oneleft panel, taken from Wei and colleagues [34], illustrates the epistatic
trate on the indicated 30 kb region. The right panel, taken from
ssociation at the SLC2A9 locus. The approximate positions of the
s [31] are arrowed. The genomic co-ordinates differ between each
build 37.3 and Scharpf and colleagues [31] used NCBI build 36. NCBI,
morphism.
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stream variant abuts a DNAse hypersensitivity peak in
fetal and adult kidney tissue, suggesting that deletion of
the 7.5-kb segment could influence binding of proteins
that regulate expression of SLC2A9 [31].
The study by Wei and colleagues [34] is consistent
with the above studies in providing evidence for multiple
independent genetic effects at the SLC2A9 locus; using
conditional analysis, they found direct evidence for five
independent genetic effects. Furthermore, additional com-
plexity in genetic control of urate levels at SLC2A9 was re-
vealed. In a genome-wide scan in 9,172 individuals of
European ancestry for epistasis (non-additive interaction)
between genetic variants in influencing urate levels, the
only genome-wide significant effects were seen for five
SNP pairs at the SLC2A9 locus, in a 30-kb region up-
stream of the WDR1 gene (Figure 3). At least one of these
was statistically independent of the aforementioned five
independent genetic effects. Collectively, the independent
SNPs and the interacting SNP pairs explained 6.0% of the
variance in urate levels in the European data set analyzed;
this is an exceptionally large effect for a genetic locus
regulating a complex phenotype. Evidence for an unusual
enrichment of chromatin interactions (mediated by en-
hancers) was found in both the WDR1-ZNF518B and
SLC2A9-WDR1 intergenic regions, which included the
interacting SNP pairs. This generates the hypothesis that
SLC2A9 and WDR1 may be co-transcribed or share tran-
scriptional regulatory machinery. As a final comment,
given that SLC2A9 is part of the renal uric acid ‘transpor-
tasome’ [35], which contains other genetically regulated
uric acid transporters and accessory molecules, it was sur-
prising that epistatic interactions between SLC2A9 and
other loci throughout the genome were not discovered by
Wei and colleagues [34]. It will be important to repeat this
genome-wide epistasis scan in larger data sets.
ABCG2
Association of the ABCG2 locus with serum urate was
first reported in the GWAS by Dehghan and colleagues
[5]. The genetic basis is considerably simpler than that
at SLC2A9, and the association signal is reported to be
driven solely by the rs2231142 (Q141K) variant [36]. This
variant is highly likely to be causal [37]. The ABCG2 pro-
tein (also known as breast cancer resistance protein) is a
multidrug transport protein transporting a wide range of
molecules, including chemotherapeutic agents. It is a
secretory uric acid transporter in the proximal tubule and
the gut [36,38]. Interestingly, the urate-increasing allele at
rs2231142 (141 K) is associated with increased urinary
uric acid output [38,39]. In mice, an Abcg2 knockout also
showed increased renal but decreased gut uric acid excre-
tion [38]. This allele was also associated with a reduced
increase in serum urate and glucose in response to afructose load [39]. Collectively, these results show that the
urate-increasing allele at ABCG2 does not act directly via
direct effects on renal uric acid transport but through in-
creased gut excretion. Histone deacetylase inhibitors are
able to correct the ABCG2 141 K urate-increasing ‘defect’
[37]. ABCG2 Q141K may also interact with extra-renal
metabolic pathways to regulate serum urate (for example,
via an influence on hepatic conversion of fructose to glu-
cose) [39]. Ichida and colleagues [38] propose that ABCG2
defines one of three pathways contributing to hyperurice-
mia, namely extra-renal uric acid under-excretion, the
other two being genuine urate over-production and renal
uric acid under-excretion.
The study by Köttgen and colleagues
The large GWAS by Köttgen and colleagues [4] reported
18 new loci with a weaker effect on urate levels than the
previously identified 10; the new 18 explained a further
1.8% of variance in urate levels compared with 5.2% for
the 10 previously known loci. Notably, none of the new
loci contained genes encoding known uric acid trans-
porters, although an association with almost genome-wide
significance was detected in the SLC2A7 locus (encoding
the organic anion transporter 2) in a candidate gene
secondary analysis. Summarized in Table 1, the study by
Köttgen and colleagues contains a treasure trove of infor-
mation on the control of urate levels.
Candidate genes at each locus were identified by Köttgen
and colleagues by using Gene Relationships Across Impli-
cated Loci (GRAIL) [40], a bioinformatic approach that
looks for commonalities between associated SNPs, the lit-
erature, and published GWASs. The GRAIL genes were
mapped into two broad pathways: glycolysis and inhibins/
activins. The relevance of the glycolysis genes to urate
likely reflects hepatic production of urate (from sugar and
alcohol) via increased generation of glucose-6-phosphate
that flows through the pentose-phosphate pathway gener-
ating ribose-5-phosphate, a precursor of purine synthesis.
Generation of lactic acid from anaerobic glycolysis could
also interfere with renal uric acid excretion. This possibility
is consistent with the strong association of the GCKR locus
with fractional excretion of uric acid (the GCKR protein
inhibits glucokinase that produces glucose-6-phosphate)
[4]. Köttgen and colleagues noted that the associations
with loci containing genes involved in glucose homeostasis
fit with the observation that drugs that decrease insulin
resistance (for example, metformin) also tend to decrease
serum urate levels, indicating possible new approaches for
management of urate levels. The relevance of the inhibins/
activins is not clear; Köttgen and colleagues [4] suggested
processes such as energy balance, insulin release, apoptosis,
inflammation, and sex hormone regulation.
There is one very important caveat in interpreting the
GWAS findings: the considerable majority of the GRAIL-
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linkage disequilibrium (intermarker correlation) results in
association signals extending for some distance across
many loci. This means that multiple candidate genes can
exist (see examples in Figure 4). To identify the causal
gene at each locus will require further genetic research,
beginning with resequencing of candidate genes in each
locus with the causal gene predicted to have a larger bur-
den of rare functional variants in extreme hyperuricemia.
This approach can be complemented by trans-ancestral
mapping with the most likely common causal variant (that
is, the effect identified by Köttgen and colleagues) pre-
dicted to be most strongly associated with urate levels
(and gout) between diverse ancestral groups. Alongside
this approach, identification of ancient recombinant hap-
lotypes that differ between ancestral groups can aid in
fine-mapping. A third approach that was employed by
Köttgen and colleagues [4] to identify likely candidate
genes is underpinned by the hypothesis that the causal
variant is an ‘eSNP’ (expression SNP) that influences the
expression of the causal gene at the locus. This is a strong
hypothesis given that approximately 70% of genetic vari-
ants for common phenotypes identified by GWASs map
to regulatory regions of the genome [41]. The authors cor-
related the significant urate-associated SNPs with expres-
sion of genes in various tissues from publically available
databases. The tissues included various white blood cells,
adipose, various neural cells, fibroblasts, osteoblasts, and
liver, although no renal tissue or cell line was analyzed. Of
the total 28 genome-wide significant loci, eight showed
strong (P < 1 × 10−4) evidence for association with multiple
expression probes. Notable in this analysis was clear evi-
dence that the intergenic association signal at the INHBB
locus (Figure 4) was associated with expression of INHBB
in the liver. This provides evidence that INHBB is the
causal gene at this locus. At ABCG2, the rs2231142 vari-
ant (Q141K), which is highly likely to be a causal variant
at this locus [36], was associated with ABCG2 expression
in the liver [4]. This is consistent with functional evidence
that the urate-increasing allele (141 K) reduces ABCG2
protein expression levels [37] and with the hypothesis that
ABCG2 (known to transport uric acid [36]) operates in
extra-renal pathways to influence urate levels [39]. There
was association with expression of both BAZ1B and
MLXIPL in adipose tissue at the BAZ1B locus. This may
reflect co-ordinated expression of closely linked genes but
is consistent with the role of MLXIPL (which encodes the
glucose-responsive transcription factor ChREBP) in
transcriptional activation of glycolytic genes. Interpret-
ation of results at the remaining five loci (TRIM46,
GCKR, SFMBT1, SLC17A1, and ATXN2) is less obvious.
For example, there was strong association with multiple
expression probes in neural expression data sets with the
CUX2 gene at the ATXN2 locus. The eSNP approach doesneed to be reapplied to the 28 urate loci by using a
wider range of tissue expression data sets that include
renal tissue and gut enterocytes from different develop-
mental stages.
There are some loci where the causal gene appears
obvious (HLF, HNF4G, IGF1R, and PRKAG2) where the
associated signal is tightly restricted within a single gene
(Table 1 and Figure 4). However, other approaches (gen-
etic and functional) are required to confirm these as the
causal genes. The FTO locus in weight control is a
salutary example. Given the tight restriction of the asso-
ciation signal to the FTO gene, it has been widely
assumed that the causal effect owes to the FTO protein.
However, it has now been shown that the weight-
associated variants in FTO interact with the promoter
of the neighboring IRX3 gene [42], suggesting that IRX3
may mediate the effect of the association signal at FTO.
Some signals are tightly restricted to an intergenic seg-
ment (INHBB, MAF, and VEGFA), indicating that urate
control is probably enhancer-mediated by control of
expression of the causal gene. These association signals
illustrate that the considerable majority of common
genetic variants associated with human phenotypes map
to functionally important regions of the genome that
regulate gene expression [41]. As illustrated by INHBB
[4], the eSNP approach will be particularly useful in
these situations.
Genetic contribution in different ancestral groups
Population groups such as Taiwanese Aborigines and
Polynesians (primarily Samoan, Tonga, Niuean, Tokelauan,
and Cook Island and New Zealand Maori) have inherently
higher serum urate levels, as evidenced by mid-20th
century epidemiological studies and prehistoric evidence
for gout [43]. The contemporary populations have gout
prevalences of more than double those of other population
groups (Europeans, for example [44]). This suggests that
an increased prevalence of urate-raising genetic variants,
some of which may be unique, contributes to urate-raising
and risk of gout. This hypothesis has generally been diffi-
cult to assess, with only urate-raising variants discovered in
Europeans examined thus far. There is, however, some in-
dication that prevalences of urate-raising alleles are higher
and effect sizes are stronger in Taiwanese Aborigines and
Polynesians [45,46]. To better evaluate the possible contri-
bution of population-specific genetic variants, known and
candidate urate loci need to be resequenced in Taiwanese
Aborigines and Polynesians.
The urate-associated genetic variants as tools for
Mendelian randomization studies
An important biomedical question is whether hyperuri-
cemia and gout are causal of associated metabolic condi-
tions such as hypertension and heart and kidney disease.
AB
C
Figure 4 LocusZoom pictures of regional association in Europeans in the study by Köttgen and colleagues [4]. The top associated
single-nucleotide polymorphism (SNP) is labeled, and other associated SNPs are colored according to strength of linkage disequilibrium (red = high;
purple = very low). –log10P is on the left-hand y-axis. (A) Illustrating multiple genes underlying a serum urate association signal at the INHBC and
TRIM46 loci. (B) Examples of association signals that define a single causal gene of high-prior probability. (C) Examples of intergenic association signals.
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founders suggest that hyperuricemia is causal. However,
these studies, no matter how well designed, cannotremove all sources of confounding. Because genetic vari-
ants associated with phenotype are biological exposures
present since conception, the biological processes they
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tenet provides the basis for the Mendelian randomization
genetic technique that is increasingly being applied to
understand biological cause-effect relationships and that
removes confounding as a fundamental issue in disen-
tangling cause-effect relationships. This technique can
be likened to a randomized clinical trial, whereby indi-
viduals are randomly assigned by nature to separate ex-
posure (allele that raises biological exposure of interest)
and control (other allele) groups at gamete formation
and conception and followed for disease outcome. Using
urate-associated genetic variants, particularly those within
the SLC2A9 locus, as surrogates for the exposure (urate)
Mendelian randomization has provided evidence that
urate is not causal for ischemic heart disease, metabolic
syndrome, reduced renal function, or increased triglycer-
ide levels [47-50].
The missing heritability in urate control: common variants
and gene-environment interaction
Heritability is defined as the proportion of phenotypic
variability that is explained by inherited genetic variants.
In humans, it is usually calculated from twin studies that
compare phenotypic concordance between mono- and
di-zygotic twin pairs. It includes all genetic effects, in-
cluding epistasis (non-additive genetic interactions) and
non-additive interactions with environmental exposures
(GxE). Heritability of urate levels is estimated to be ap-
proximately 60% [51]. Typical of the situation for other
complex phenotypes, the proportion of variance in urate
levels explained by common genetic variants detected by
GWAS is low (7.0%) [4], accounting for only a small
proportion of the genetic component. This problem has
been termed the ‘missing heritability’ [52], with the ex-
planation(s) for this phenomenon unresolved.
In GWAS data sets, calculations to estimate the contri-
butions of SNPs to heritability use cross-sectional case–
control data. These yield the ‘narrow-sense’ heritability
(h2), in which only the heritability from the average effect
of genetic variants acting independently (additively) is esti-
mated and contributions from epistasis and non-additive
gene-environment (GxE) interactions are ignored. There
are various theories to explain the missing heritability: (a)
that common causal variants of weak effect go undetected
in GWASs, (b) that undetected rare variants with larger
effect sizes contribute, (c) that the heritability estimates
of known genetic variants that are derived from the
narrow-sense models are under-estimated owing to the
unaccounted contribution of epistasis between loci, and
(d) similarly that narrow-sense heritability estimates are
under-estimated because of the unaccounted for contri-
bution of non-additive GxE effects. In control of urate,
there is evidence to support possibility (a); 27% to 41%
(depending on the data set) of heritability is explainedwhen all common SNPs and not just the statistically sig-
nificant SNPs are considered [4]. It will be possible to
address possibility (b) when all genetic variation can be
evaluated from large whole-genome sequence data sets.
Improvement in analytical approaches and computational
power will allow testing of (c) from current GWAS data.
Regarding (d), there is evidence that non-additive GxE
interactions will explain an under-appreciated proportion
of the missing heritability in urate. In addition to the
SLC2A9-SSB interaction discussed previously [26], there is
non-additive interaction between alcohol exposure and
the lipoprotein receptor-related protein 2 gene (LRP2)
(rs2544390) in the risk of gout in Polynesian populations,
where the protective effect of the T-positive genotype is
negated by exposure to alcohol [53]. Finally, a non-
additive interaction between diuretic use and genotype
at each of SLC2A9 and SLC22A11 in the risk of gout in
hypertensive people has been reported in the Atheroscler-
osis Risk in Communities study [54]. These findings,
subject to wider replication and support from interven-
tional studies, also raise the possibility of personalized ap-
proaches to the management of hyperuricemia.
Association of the urate loci with gout
As expected, most of the urate loci are also risk factors
for gout [4,12,13], with only four loci (INHBB, HNF4G,
UBE2Q2, and BCAS3) yet to be formally associated with
gout at a nominal level of significance. Use of larger gout
case sample sets should enable this to be done. The
urate-raising allele in Europeans is associated with in-
creased risk of gout in the considerable majority of cir-
cumstances, including in Polynesians [12]. Exceptions to
this are PRKAG2 and HLF where the European urate-
raising allele protects from gout in Polynesians [12]. This
observation could be useful in fine-mapping the causal
variant at each locus under the hypothesis that the asso-
ciated SNPs (rs10480300 and rs7224610) are not causal
and that there is a recombinant haplotype differentiating
gout risk at these loci. The causal variant can be expected
to map to surrounding DNA where the same allele of gen-
etic variants would consistently associate with risk of gout
in both ancestral groups.
While correlation between increased effect size on
urate and effect size on gout is seen [4], it is logical to
expect that genetic variants with a similar effect on
serum urate should have a similar effect on the risk of
gout. However, this is not necessarily the case. The risk
alleles of GCKR, SLC16A9, SLC22A11, and INHBC are
associated with an average increase in serum urate of
0.004 mmol/L [4]. Of these loci, GCKR has an effect size
that is consistently higher in gout; GCKR is associated
with gout in European, Chinese, Japanese, and Polynes-
ian sample sets (odds ratio (OR) = 1.3 to 1.5 in sample
sets where gout is clinically ascertained) [4,12,13,55].
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Polynesian though with a lower OR of approximately
1.15 [4,12]. In contrast, SLC22A11 is not consistently
associated with gout, and the evidence for association
reported by Köttgen and colleagues [4] in Europeans
(OR = 1.14) has not been replicated elsewhere (OR =
0.98) [45]. The even weaker evidence for association of
SLC16A9 with gout in Köttgen and colleagues [4] (OR =
1.10, P = 0.017) was also not replicated elsewhere (OR =
1.01) [12]. So there are clearly inconsistent effects on as-
sociation with gout among the four loci with very similar
effects on serum urate. These observations may result
from a lack of independence between molecular path-
ways of serum urate control and clinical presentation of
gout in the presence of hyperuricemia (that is, pleiotropic
effects of the urate-associated loci) or from confounding
of serum urate and risk of gout effect sizes by unmeasured
or unaccounted for environmental exposures (for ex-
ample, as seen at SLC2A9) or from both. In future clin-
ical and epidemiological studies, it will be important to
investigate why loci such as SLC16A9 and SLC22A11 in-
consistently associate with gout.
Genetics of gout in the presence of hyperuricemia
The heritability of gout is unclear, and the only twin
study reported a wide 95% confidence interval (0% to
58.1%) [51]. Despite this uncertainty, it is reasonable to
expect that genetic variants control the development of
gout in the presence of hyperuricemia; although hyper-
uricemia is necessary for gout, it is not sufficient as not
all hyperuricemic people develop gout. The strongest
candidate genes are those influencing the innate immune
recognition of and response to MSU crystals, although
genes involved in MSU crystal formation are possible.
However, there is only one replicated association of an im-
mune gene with gout: an SNP within the candidate TLR4
innate immune gene is associated with gout in Chinese
(OR = 1.42, P < 1 × 10−4) [56]. This association was not
evident in Europeans when unstratified controls are used
(OR = 1.26, P = 0.10). Importantly, however, the effect size
increases considerably and the association is statistically
significant when asymptomatic hyperuricemic controls are
used (OR = 1.63, P = 0.009) [57].
The largest gout GWAS published to date used 3,000
European cases nested within the cohorts used in the
urate GWAS by Köttgen and colleagues [4]. The gout
GWAS yielded disappointing results; only SLC2A9 and
ABCG2 were associated at a genome-wide level of sig-
nificance. A major reason for this is the phenotyping
where cases were ascertained by self-report or the use of
allopurinol (which is also used in asymptomatic hyper-
uricemia) or both, resulting in ‘case’ sample sets that will
include participants without gout. The SLC17A1 locus
has the third strongest effect on serum urate [4] and hasbeen associated with gout in candidate gene studies in
Japanese, European, and Polynesian sample sets ascer-
tained by clinical assessment, where the OR was consist-
ently approximately 1.5 [58,59]. Notably, the effect size
for SLC17A1 in the aforementioned gout GWAS was con-
siderably weaker at an OR of 1.16 [4]. Although there was
significant association when the locus was specifically
tested (P = 0.01), the weaker effect meant that the signal
was hidden in the statistical noise inherent in a GWAS.
Thus, there is a need for a gout GWAS in clinically ascer-
tained sample sets in order to identify non-serum urate
genetic risk factors for gout (for example, TLR4) which
are likely to have weak effects (OR <1.4). Ideally, such a
GWAS would use people with asymptomatic hyperurice-
mia as controls, who would be expected to have inherited
genetic variants protecting from development of gout in
the presence of hyperuricemia.
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